Syed Haider Abbas, MD
Rheumatology · Lexington, KYNPI 1982658902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,081 and has fallen 54.0% since, to $497 in 2025.
Across 105 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$468
- Shionogi Inc$337
- Novartis$259
- Amgen$243
- UCB, Inc.$205
- Johnson & Johnson$199
- plus $986 from 17 others
What the payments were for
- Food & beverage$2,697100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $468 |
| Shionogi Inc | 12 | $337 |
| Novartis | 10 | $259 |
| Amgen | 11 | $243 |
| UCB, Inc. | 8 | $205 |
| Johnson & Johnson | 8 | $199 |
| E.r. Squibb & Sons, L.L.C. | 4 | $175 |
| Acadia Pharmaceuticals Inc | 1 | $114 |
| Boehringer Ingelheim | 5 | $111 |
| Pfizer | 6 | $110 |
| Lilly USA, LLC | 4 | $75 |
| Sandoz | 3 | $65 |
| Sobi, Inc | 2 | $51 |
| Sanofi | 2 | $48 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| GSK | 2 | $37 |
| AstraZeneca | 2 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Bristol Myers Squibb | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,697 in reported general payments places this provider in the 55th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 273 | $2,077,069 |
| RinvoqUpadacitinib | 74 | $565,104 |
| Humira(Cf) PenAdalimumab | 67 | $561,743 |
| Xeljanz XrTofacitinib Citrate | 74 | $424,081 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 56 | $416,519 |
| EnbrelEtanercept | 25 | $235,167 |
| Humira PenAdalimumab | 28 | $215,338 |
| OtezlaApremilast | 41 | $209,090 |
| XeljanzTofacitinib Citrate | 36 | $199,509 |
| HumiraAdalimumab | 25 | $168,936 |
| ActemraTocilizumab | 30 | $153,284 |
| Orencia ClickjectAbatacept | 21 | $128,952 |
| KevzaraSarilumab | 29 | $125,541 |
| RemicadeInfliximab | 19 | $115,718 |
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $97,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Savella | $468 | $758,366124 claims |
| AmgenEnbrel, Otezla | $243 | $444,25766 claims |
| PfizerXeljanz | $110 | $199,50936 claims |
| Johnson & JohnsonRemicade, Simponi | $199 | $193,44932 claims |
| SanofiKevzara | $48 | $125,54129 claims |
| UCB, Inc.Cimzia (2 Pack) | $205 | $97,11217 claims |
| GSKBenlysta | $37 | $48,15313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Lexington
- Alexander BrownLexington$10K
- Kelly ColeLexington$9K
- Paramarajan PiranavanLexington$8K
- Elaine AlexanderLexington$8K
- Lucia HardiLexington$7K
- Izabela AnticLexington$5K
- Corey HatfieldLexington$4K
- Jeffrey NealLexington$3K
- Amna BatoolLexington$2K
- Robert LightfootLexington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.